Recent Finacing
Recent Raise
SAGE Therapeutics develops CNS medicines using a PANAM allosteric‑modulator platform targeting GABAA and NMDA receptors, advancing IV and oral candidates for status epilepticus, Fragile X, TBI, depression.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors